Case examples of FDA decisions explicitly citing real world evidence Case Examples of FDA Decisions Explicitly Citing Real World Evidence In the evolving landscape of pharmaceutical and medical device approvals, the role of Real-World Evidence (RWE) has intensified, necessitating a more nuanced understanding among regulatory professionals. The FDA has established a framework for incorporating RWE into its regulatory decision-making, signaling a pivotal shift toward integrating non-traditional data sources alongside randomized controlled trials (RCTs). This article delves into the FDA’s framework for RWE utilization, presenting case examples where RWE has influenced decision-making for drug and device approvals. It aims to provide…

Common Misconceptions About What FDA Will and Will Not Accept as RWE Real-World Evidence (RWE) has emerged as a significant tool in the regulatory landscape, particularly for drug and device approvals by the FDA. However, a myriad of misconceptions exists regarding the framework that governs the acceptance of RWE in regulatory decisions. This article serves as a comprehensive tutorial designed for regulatory, biostatistics, health economics and outcomes research (HEOR), and real-world data (RWD) professionals in the pharmaceutical and medtech industries. We will delve into the FDA framework for real-world evidence approvals, clarifying what is acceptable under current guidelines and countering…

Leveraging FDA RWE Guidance to Prioritize Data Partnerships and Platforms Leveraging FDA RWE Guidance to Prioritize Data Partnerships and Platforms The FDA’s framework for real-world evidence (RWE) approvals presents numerous opportunities for regulatory, biostatistics, health economics and outcomes research (HEOR), and data standards professionals in the pharmaceutical and medtech sectors. This tutorial will guide you through the various aspects of the FDA’s RWE guidance, with steps to implement effective data partnerships and platforms. By emphasizing the importance of the totality of evidence in drug and device approvals, we aim to provide detailed, actionable insights for stakeholders in the RWE landscape….

RWE Framework Checklist for Regulatory, HEOR and Safety Leaders Introduction to Real-World Evidence and FDA Guidance The modern landscape of pharmaceutical and medical device development is grappling with how to effectively incorporate Real-World Evidence (RWE) in regulatory decision-making. The FDA’s framework for RWE is pivotal for ensuring that evidence derived from real-world data meets the rigorous standards required for product approvals. This tutorial seeks to provide a comprehensive checklist that regulatory professionals, Health Economics and Outcomes Research (HEOR) specialists, and safety leaders can apply when navigating the FDA framework for RWE in drug and device approvals. Understanding RWE is crucial…

Governance Models for Enterprise Level RWE Strategy in Pharma Companies In the evolving landscape of drug and device approvals, Real-World Evidence (RWE) has emerged as a pivotal component influencing regulatory decisions. This article provides a comprehensive step-by-step tutorial on developing governance models to effectively integrate RWE into enterprise-level strategies in the pharmaceutical and medtech sectors, particularly within the scope of the FDA framework for real-world evidence approvals. Understanding the FDA Framework for RWE The FDA framework for real-world evidence approvals is fundamentally aimed at enhancing the understanding of drug and device efficacy and safety based on actual usage outside of…

Using Digital Health and Wearable Data Streams as Real World Data Sources The integration of digital health technologies and wearable data into clinical research presents an unprecedented opportunity for pharmaceutical and medtech professionals. As part of the ongoing evolution in the healthcare landscape, real world data (RWD), which includes data from various sources such as claims, electronic health records (EHRs), patient registries, and wearable devices, has gained significant attention for its potential to support regulatory decision-making and improve patient outcomes. This step-by-step tutorial provides a comprehensive overview of how to utilize digital health and wearable data streams as real world…

Designing Disease and Product Registries that Meet FDA RWE Expectations Introduction to Real-World Evidence (RWE) and Registries In the evolving landscape of healthcare, increasingly diverse sources of data are being utilized to support regulatory decision-making and post-market surveillance. Real-world evidence (RWE) provides insights derived from real-world data (RWD), which includes data on patient health outcomes and healthcare utilization, often captured through electronic health records (EHR), claims data, registries, and digital health platforms. As regulatory agencies, especially the US FDA, emphasize integrating RWE into their frameworks, professionals in pharma and medtech must understand how to design disease and product registries that…

Leveraging EHR Data for Regulatory Grade Real World Evidence Studies In recent years, there has been a growing emphasis on the utilization of Real World Data (RWD) within the pharmaceutical and medical technology sectors. This has largely been driven by the need for evidence that supports the effectiveness and safety of products in current clinical settings. Electronic Health Records (EHR) serve as a critical foundation for much of this research. This tutorial aims to provide a detailed, step-by-step approach on how to leverage EHR data for regulatory-grade Real World Evidence (RWE) studies, tailored for professionals in regulatory affairs, biostatistics, health…

Strengths and Weaknesses of Claims Databases for RWE Generation Real-world data (RWD) generation has become a pivotal aspect of evidence generation in healthcare. It leverages diverse data sources, including claims databases, electronic health records (EHRs), patient registries, and digital health data, to enhance decision-making in medical product development, regulatory review, and post-market evaluations. This article provides a detailed exploration of the strengths and weaknesses of claims databases as a source for generating real-world evidence (RWE), while aligning with US FDA expectations and considering EU and UK perspectives. Understanding Claims Databases Claims databases consist of records created when healthcare services are…

Comprehensive Overview of Real-World Data Sources: Claims, EHR, Registries, and Digital Health Data The evolution of healthcare delivery has been influenced significantly by the integration and utilization of real-world data (RWD) in decision-making processes. This article will provide an in-depth analysis of real-world data sources, including claims data, electronic health records (EHR), patient registries, and digital health data, particularly in the context of United States Food and Drug Administration (FDA) regulations and guidance. Understanding Real-World Data and Evidence: Defining the Terms Real-world data (RWD) refers to data collected from various sources, outside traditional controlled clinical trials, that reflect the outcomes…